Stonepine Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Stonepine Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,597	Closed	-$2.52M	–	61
2025 Q2	$2.52M	Sell	38,597 -9,403	-20%	-$612K	2.47%	13
2025 Q1	$13.6M	Buy	48,000 +27,600	+135%	+$1.65M	13.28%	1
2024 Q4	$1.13M	Buy	+20,400	New	+$1.17M	0.91%	28
2022 Q3	–	Sell	-28,800	Closed	-$854K	–	20
2022 Q2	$854K	Buy	28,800 +2,740	+11%	+$79K	0.4%	23
2022 Q1	$733K	Sell	26,060 -26,230	-50%	-$978K	0.3%	26
2021 Q4	$2.41M	Buy	+52,290	New	+$2.25M	1.11%	19
2016 Q2	–	Sell	-1,650	Closed	-$56K	–	24
2016 Q1	$56K	Buy	+1,650	New	+$56K	0.07%	17

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Stonepine Capital Management's ANIP Position: Q3 2025 in Review

Stonepine Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2025, closing a stake of 38,597 shares — an estimated $2.52M sold.

Stonepine Capital Management first reported a position in ANIP in Q1 2016 and held it in 7 quarters. The position peaked at $13.6M in Q1 2025. 269 funds tracked by Wall St. Rank hold ANIP as of Q3 2025.

Stonepine Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Stonepine Capital Management sold 38,597 ANI Pharmaceuticals shares in Q3 2025, an estimated $2.52M.
Stonepine Capital Management first reported a position in ANI Pharmaceuticals in Q1 2016 and held it in 7 quarters.
Stonepine Capital Management's ANI Pharmaceuticals position peaked at $13.6M in Q1 2025.
269 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.